Role of Mediastinoscopy in Pretreatment Staging of Patients with Primary Lung Cancer

https://doi.org/10.1016/S0003-4975(10)60348-7Get rights and content

Abstract

Since the introduction of mediastinoscopy, there has been a great deal of discussion regarding indications for this technique and the significance of positive findings. We undertook this study to determine the role of clinical staging and the value of routine mediastinoscopy in the treatment selection of patients with primary lung cancer.

From 1975 to 1983, 1,259 consecutive patients with proven and operable lung cancer underwent preresection mediastinoscopy. Nodes were sampled at three levels, and findings were recorded by location, invasiveness, and histology. There were no operative deaths, but 3 patients had a major complication.

Mediastinoscopy was positive in 339 (27%) patients and negative in 920 (73%). In the group with positive findings, 303 patients had no operation because a curative resection was not possible (extranodal metastases, 180; location, 76; histology, 47). No patient survived 5 years, and only 4% survived 2 years. Of the 36 patients considered to have operable disease, 28 underwent resection with a projected 5-year survival of 18%. In the group with negative findings, 89% had a curative resection with a hospital mortality of 3.2% and 5-year survival of 53%. When results of mediastinoscopy were correlated with findings at thoracotomy, the sensitivity of the test was 93% on nodes in the superior mediastinum and the specificity, 100%.

This study shows that mediastinoscopy is safe and is an accurate indicator of the presence or absence of tumor in superior mediastinal nodes. If positive nodes are found, a curative resection is generally not possible, thoracotomy is avoided, and the overall survival is low.

References (30)

Cited by (178)

  • Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines

    2013, Chest
    Citation Excerpt :

    Most of these studies involved patients with clinical stage I disease and do not provide relevant guidance on what is best for patients with stage cIII disease. In the case of intraoperatively identified N2 involvement, it seems reasonable to suggest that a complete MLND be performed, even though survival data are not available (given that the morbidity of MLND has been consistently found to be minimal).90,95–97,99,100 It is important to emphasize that outcomes data for occult N2 involvement (including that of subgroups) are primarily in patients who were thoroughly staged preoperatively.

  • Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines

    2013, Chest
    Citation Excerpt :

    Furthermore, in 40% of patients with cytologically negative pleural effusions, the effusions were shown not to be due to malignant involvement by VATS.262 On the other hand, routine VATS found unsuspected pleural studding in 4% (0%–5%) of patients in several studies.137,260,261,264–267 An unsuspected malignant pleural effusion was also found in 6% in one study.265

  • Bronchoscopy in lung cancer: Where are we going?

    2011, Revista de Patologia Respiratoria
  • Mediastinoscopy and Mediastinotomy

    2010, Medical Management of the Thoracic Surgery Patient
View all citing articles on Scopus

Presented at the Twenty-first Annual Meeting of The Society of Thoracic Surgeons, Phoenix, AZ, Jan 21–23, 1985.

This work was entirely supported by the Chaire de Pneumologie de Laval, Fondation J.D. Bégin.

View full text